P2Y₁₂ receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial

详细信息    查看全文

• 作者：Leonardo de F.C. Guimarã ; es^a ; Philippe Gé ; né ; reux^b ; ^c ; ^d ; ^e ; Diego Silveira^a ; Antonio Eduardo Pesaro^f ; Felipe Falcã ; o^a ; Bruno Robalinho C. Barbosa^a ; Cristiano Freitas de Souza^a ; Francisco A.H. Fonseca^a ; Clá ; udia Maria Rodrigues Alves^a ; Antô ; nio Carlos de Camargo Carvalho^a ; Gregg W. Stone^b ; ^c ; Adriano Caixeta^a ; ^f ; ^{adriano.caixeta@einstein.br}
• 关键词：Ticagrelor ; Prasugrel ; Fibrinolysis ; Acute myocardial infarction
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 March 2017
• 年：2017
• 卷：230
• 期：Complete
• 页码：204-208
• 全文大小：317 K
• 卷排序：230

文摘

Fibrinolytic agents may stimulate platelet hyperactivity. High platelet reactivity is related to occurrence of ischemic events. Clopidogrel, in pharmacoinvasive strategy, showed suboptimal platelet inhibition. Prasugrel and ticagrelor have a slow action peak after fibrinolysis. The pharmacodynamics of prasugrel and ticagrelor are similar after fibrinolysis.